Since taking effect in August 2024, the EU AI Act (Regulation (EU) 2024/1689) has categorised AI tools by risk level. For ...

Shares in Abivax were tracking up this morning as a media report in France suggested a takeover by Eli Lilly – worth €15 billion ($17.5 billion) – could be on the cards. French newspaper La Lettre ...

The much-anticipated pricing agreement between Novo Nordisk and Eli Lilly and the Trump administration on GLP-1 drugs has arrived, with a deal that spans the current injectable products as well as ...

Jean-François Toussaint, Sanofi's global head of vaccines R&D, speaking at a conference at the company's site in Lyon last year. There are currently no approved vaccines to protect against chlamydia – ...

England is on track to be one of the first countries in the world to eliminate the hepatitis C virus (HCV), thanks to a pioneering antiviral drugs programme. Since 2015, around 100,000 people have ...

Jazz Pharmaceuticals has agreed another pipeline-building deal, this time paying $10 million upfront for rights to a KRAS inhibitor programme from UK biotech Redx Pharma, continuing a move into ...

Shares in Novo Nordisk were up nearly 12% today – hiking its valuation to more than $280 billion – after it reported new clinical data with one of its obesity drug candidates. The new results with a ...

Roche is moving its novel antibiotic zosurabalpin into phase 3 testing for carbapenem-resistant Acinetobacter baumannii (CRAB), a 'superbug' that is considered an 'urgent threat' by the CDC, in what ...

AstraZeneca and Daiichi Sankyo's anti-HER2 drug Enhertu has been shown to provide a benefit in a phase 3 trial in early-stage breast cancer for the first time, setting up regulatory filings. The ...

Novo Nordisk has asked the FDA to stop compounding pharmacies making cheaper versions of its semaglutide-based therapies for obesity and diabetes, saying the drug is too complex to be made safely by ...

A digital therapy that could reduce the severity of chronic tic disorders like Tourette syndrome has been recommended for use by the NHS for the first time. The technology, known as ORBIT (Online ...

It’s been almost a decade since Japanese pharma company Daiichi Sankyo began its dramatic pivot from cardiovascular health into antibody-drug conjugates. For Daiichi Sankyo, it’s hard to argue that ...